Aurora Cannabis Inc. (NASDAQ:ACB) Q4 2024 Earnings Conference Call June 20, 2024 8:00 AM ET
Company Participants
Kevin Niland - Director, Strategic Finance and IR
Miguel Martin - CEO
Simona King - CFO
Conference Call Participants
Matt Bottomley - Canaccord
Eric Livshits - ATB Capital Markets
John Zamparo - CIBC
Pablo Zuanic - Zuanic Associates
Operator
Greetings and welcome to the Aurora Cannabis Inc. Fourth Quarter 2024 Results Conference Call. All participants will be in a listen-only mode and a question-and-answer session will follow the formal presentation. This conference is being recorded today, Thursday, June 20, 2024.
I would now like to turn the conference over to your host, Kevin Niland, Director of Strategic Finance and Investor Relations. Please go ahead, sir.
Kevin Niland
Hello, everyone, and thank you for joining us. On the line with me are Miguel Martin, CEO, and Simona King, CFO. This morning, we filed our 2024 fiscal year and fourth quarter financials for the period ending March 31, 2024, and issued a news release containing both our annual and quarterly results.
Our financial statements, MD&A and this news release are available on our IR website and also accessed via SEDAR+ and EDGAR. In addition, you will find a supplemental information deck on our IR website. For today's conference call, listeners are reminded that certain matters could constitute forward-looking statements that are subject to risks and uncertainties related to our future or financial or business performance. Actual results could differ materially from those anticipated in those forward-looking statements.
The risk factors that may affect actual results are detailed in our annual information form and other periodic filing and registration statements. These may be accessed or may similarly be accessed via SEDAR+ and on EDGAR. Following prepared remarks by Miguel and Simona we will conduct a question-and-answer session with our covering analyst.
With that, I'll turn the call over to Miguel. Please go ahead.
Miguel Martin
Thank you, Kevin. We are very pleased to report that 2024 was our strongest ever fiscal year. I'll highlight some specific metrics related to our performance momentarily, but more generally we believe our accomplishments can best be attributed to the following. First, our business model is centered on our medical cannabis leadership within nationally legal markets. Aurora's frontline positioning in the industry's highest margin segment is the direct result of the competitive advantage we built through a manufacturing network of indoor EUGMP certified facilities that serve the diverse needs of our patients across the world.